{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:55:28Z","timestamp":1792796128652,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1007\/s11864-000-0018-9","type":"journal-article","created":{"date-parts":[[2007,7,26]],"date-time":"2007-07-26T08:52:11Z","timestamp":1185439931000},"page":"83-89","source":"Crossref","is-referenced-by-count":33,"title":["Primary systemic amyloidosis"],"prefix":"10.1007","volume":"1","author":[{"given":"Raymond L.","family":"Comenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0025-6196(11)65130-6","volume":"74","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A: Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 1999, 74:490\u2013494. This is a consise review designed to alert the primary care physician to the signs and symptoms of amyloid lightchain amyloidosis","journal-title":"Mayo Clin Proc"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2141.1997.303194.x","volume":"99","author":"JD Gillmore","year":"1997","unstructured":"Gillmore JD, Hawkins PN, Pepys MB: Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 1997, 99:245\u2013258. In this review, a comprehensive therapeutic algorithm is offered to guide decisions regarding the treatment of AL patients","journal-title":"Br J Haematol"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M: The systemic amyloidoses: current approaches to diagnosis and treatment. N Engl J Med 1997, 337:898\u2013910. In this review, a broad account of the various forms of amyloidosis and their presentation is offered with helpful diagnostic guidelines","journal-title":"N Engl J Med"},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.510250122","volume":"25","author":"MA Gertz","year":"1997","unstructured":"Gertz MA, Kyle RA: Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology 1997, 25:118\u2013121.","journal-title":"Hepatology"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0002-9343(98)00037-0","volume":"104","author":"SV Rajkumar","year":"1998","unstructured":"Rajkumar SV, Gertz MA, Kyle RA: Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med 1998, 104:232\u2013237.","journal-title":"Am J Med"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.92.21.9490","volume":"92","author":"N Schormann","year":"1995","unstructured":"Schormann N, Murell JR, Liepnieks JJ, Benson MD: Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proc Natl Acad Sci USA 1995, 92:9490\u20139500.","journal-title":"Proc Natl Acad Sci USA"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","volume":"336","author":"R Kyle","year":"1997","unstructured":"Kyle R, Gertz M, Greipp P, et al.: A trial of three regimes for primary amyloidosis: colchicine alone, melphalan and prednisolone, and melphalan, prednisolone and colchicine. N Engl J Med 1997, 336:1202\u20131207. This is one of the largest clinical trials ever conducted in AL amyloidosis and confirms a role for cytoreductive therapies","journal-title":"N Engl J Med"},{"key":"18_CR8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson JJ, Simms R, et al.: Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine alone. Am J Med 1996, 100:290\u2013298.","journal-title":"Am J Med"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/BF02785843","volume":"16","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Lust JA, et al.: Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999, 16:104\u2013109.","journal-title":"Med Oncol"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.1999.17.1.262","volume":"17","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Lust JA, et al.: Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999, 17:262\u2013267.","journal-title":"J Clin Oncol"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","volume":"91","author":"RL Comenzo","year":"1998","unstructured":"Comenzo RL, Vosburgh E, Falk RH, et al.: Doseintensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662\u20133670. This is the report of a phase II trial using stem cell transplant to treat 25 patients with AL. The benefits of stem cell transplant are well described with respect to the reversal of AL organ involvement","journal-title":"Blood"},{"key":"18_CR12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2141.1999.01216.x","volume":"104","author":"RL Comenzo","year":"1999","unstructured":"Comenzo RL, Sanchorawala V, Fisher C, et al.: Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CFS or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999, 104:553\u2013564. In this report of a phase II trial, AL patients received lower doses of intravenous melphalan with stem cells in an attempt to extend the benefits of intravenous melphalan to older and sicker patients. Although some patients benefitted, the transplant-related 100 day mortality remained 20%, and the need for better patient selection is discussed","journal-title":"Br J Haematol"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.bmt.1701925","volume":"24","author":"F Patriarca","year":"1999","unstructured":"Patriarca F, Geromin A, Fanin R, et al.: Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura. Bone Marrow Transplant 1999, 24:433\u2013435.","journal-title":"Bone Marrow Transplant"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.bmt.1701765","volume":"23","author":"O Sezer","year":"1999","unstructured":"Sezer O, Schmid P, Shweigert M, et al.: Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 1999, 23:967\u2013969.","journal-title":"Bone Marrow Transplant"},{"key":"18_CR15","unstructured":"Comenzo RL: Hematopoietic transplantation for primary systemic amyloidosis: what have we learned? Leuk Lymphoma. In press. This review provides an overview of the initial 4 years of stem cell transplant for AL with an emphasis on prognostic factors and the risks of stem cell transplant."},{"key":"18_CR16","first-page":"60","volume":"32","author":"G. Merlini","year":"1995","unstructured":"Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995, 32:60\u201379. This is an excellent review of supportive care measures that are important for managing the many symptoms of systemic amyloidosis","journal-title":"Semin Hematol"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V93.3.1112","volume":"93","author":"G Merlini","year":"1999","unstructured":"Merlini G, Anesi E, Garini P, et al.: Treatment of AL amyloidosis with 4\u2018-lodo-4\u2019-deoxydoxorubicin: an update [letter]. Blood 1999, 93:1112\u20131113.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0018-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-000-0018-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-000-0018-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T10:42:45Z","timestamp":1587811365000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-000-0018-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s11864-000-0018-9","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}